United Homes Group stock plunges after Nikki Haley, directors resign
Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biotech company with a market capitalization of $44.7 million and showing a strong 30.4% year-to-date return, reported the results of its 2025 Annual Meeting of Stockholders held Friday, according to a statement based on a recent SEC filing. According to InvestingPro analysis, the company maintains a solid financial position with more cash than debt on its balance sheet.
Shareholders elected six directors to serve until the 2026 annual meeting. The directors elected were Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Lee T. Schalop, and David S. Silberstein. Votes in favor for each director ranged from approximately 2,202,401 to 2,214,833 shares, with votes withheld ranging from 31,973 to 44,405 shares. There were 5,189,274 broker non-votes for each director nominee. The company’s financial health score from InvestingPro is rated as "Fair," with particularly strong momentum scores in recent months.
In addition to the board elections, shareholders approved a one-time repricing of certain stock options granted under the Second Amended and Restated Lantern Pharma Inc . 2018 Equity Incentive Plan, as amended. The proposal received 1,458,333 votes in favor, 758,870 votes against, and 29,603 abstentions. There were 5,189,274 broker non-votes on this item.
Shareholders also ratified the appointment of EisnerAmper LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The ratification received 7,365,922 votes in favor, 43,732 votes against, and 26,426 abstentions. There were no broker non-votes for this proposal.
Lantern Pharma is incorporated in Delaware and its common stock is listed on the Nasdaq Stock Market under the symbol LTRN. The information in this article is based on a statement from the company’s SEC filing.
In other recent news, Lantern Pharma announced that its cancer drug LP-184 achieved all primary endpoints in a Phase 1a clinical trial, showcasing a favorable safety profile and promising antitumor activity in patients with advanced solid tumors. The trial involved 63 patients, with 48% of evaluable cancer patients experiencing clinical benefits at or above the therapeutic dose threshold. Additionally, Lantern Pharma completed a Type C meeting with the FDA regarding its planned pediatric clinical trial for central nervous system cancers, receiving guidance on trial design and potential combination therapies.
Lantern Pharma’s subsidiary, Starlight Therapeutics, received FDA clearance for an Investigational New Drug application to evaluate STAR-001 in combination with spironolactone for glioblastoma multiforme patients. The company also completed patient enrollment ahead of schedule for its Phase 2 HARMONIC trial in Japan, focusing on never-smoker patients with non-small cell lung cancer. Furthermore, Lantern Pharma appointed Lee T. Schalop, M.D. to its board of directors, following a recommendation from its Nominating and Corporate Governance Committee. Dr. Schalop brings extensive experience from his previous roles in the pharmaceutical and financial industries.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.